(Q40152780)

18 September 2017

title

Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells (English)

1 reference

18 September 2017

main subject

lymphoblastic leukemia

1 reference

Zhang B

1

1 reference

18 September 2017

Groffen J

series ordinal

2

1 reference

18 September 2017

Heisterkamp N

series ordinal

3

1 reference

18 September 2017

publication date

29 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

21

1 reference

18 September 2017

issue

6

1 reference

18 September 2017

page(s)

1189-1197

1 reference

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Protein prenylation: a pivotal posttranslational process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Punish the parent not the progeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Identification of the haematopoietic stem cell niche and control of the niche size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Bone-marrow haematopoietic-stem-cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Convergence of Wnt, beta-catenin, and cadherin pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Novel target genes of the Wnt pathway and statistical insights into Wnt target promoter regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarb

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404667

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2404667

1 reference

Dimensions Publication ID

18 September 2017

1031984401

0 references

1 reference